Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib
Table 2
PET results for desmoid patients () treated with imatinib.
Patient no.
Age (years)
Tumor localization
Imatinib treatment duration (months)
Average SUV (initial)
Average SUV (follow-up)
SUV change (%)
Response according to RECIST
PFS (months)
1
64
Chest
6
2.902
2.538
PD
6
2
70
Pelvis
5
3.171
3.364
SD
5
3
31
Retroperitoneal
74
4.233
3.294
PR
74+
4
42
Mesenterium
4
3.023
2.793
PD
4
5
22
Chest
15
3.320
1.711
SD
15
6
35
Supraclavicular
6
2.115
1.851
SD
6
7
27
Upper limb
58
3.112
2.428
SD
58+
8
70
Buttock
60
2.785
2.632
SD
60+
9
38
Pelvis
49
2.376
1.735
SD
49+
10
68
Shoulder
12
2.098
1.458
PD
12
11
43
Upper limb
8
2.100
1.600
PD
8
12
48
Pelvis
9
2.900
2.800
SD
9+
13
40
Pelvis
26
3.500
2.100
PR
26+
14
47
Upper limb
28
2.300
1.800
PR
28+
15
54
Chest
1
5.229
3.100
SD
22
16
30
Pelvis
18
3.074
2.400
SD
18+
17
24
Mesenterium
17
11.573
1.981
SD
16+
18
48
Chest
3
2.059
1.975
PD
3
19
41
Buttock
15
2.000
2.100
PR
15+
20
70
Parascapular
13
2.900
2.114
PR
13+
21
39
Fossa ischiorectalis
5
2.492
2.100
SD
5+
22
75
Mesenterium
1
4.037
n.e.
n.e.
SD
1+
SUV: standardized uptake value; RECIST: Response Evaluation Criteria in Solid Tumors; PFS: progression-free survival; PR: partial response; PD: progressive disease; SD: stable disease; n.e.: not evaluable; +: patient is still progression-free at the time of data collection and continues treatment with imatinib.
